Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: Kinetics and structural requirements

Drug Metabolism and Disposition

Volumn 30, Issue 11, 2002, Pages 1194-1200

  Hutzler, J Matthew ^a   Kolwankar, Dhanashri ^a   Hummel, Matthew A ^a   Tracy, Timothy S ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 NITROPHENYLSULFONYL)ANILINE; 4 TOLYLSULFONE; BENZOPHENONE; CARBONYL DERIVATIVE; CYTOCHROME P450 2C9; DAPSONE DERIVATIVE; DICYCLOHEXYL KETONE; DIPHENYL SULFONE; FLURBIPROFEN; FUNCTIONAL GROUP; KETOPROFEN; NAPROXEN; SULFADIAZINE; SULFADIMIDINE; SULFAMETHOXAZOLE; SULFONAMIDE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; CYP2C9 PROTEIN, HUMAN; DAPSONE; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; UNSPECIFIC MONOOXYGENASE;

ANIMAL CELL; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG ACTIVATION; DRUG BINDING; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME METABOLISM; ENZYME SUBSTRATE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ALGORITHM; DEALKYLATION; ENZYME SPECIFICITY; HYDROXYLATION; KINETICS; METABOLISM; SYNTHESIS;

ANIMALIA;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; DAPSONE; DEALKYLATION; FLURBIPROFEN; HYDROXYLATION; KINETICS; NAPROXEN; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0036842029     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.11.1194     Document Type: Article

References (26)

1. Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, and Masimirembwa CM (2001) Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol 59:909-919.
2. Atkins WM, Wang RW, and Lu AYH (2001) Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: A prospective based on conformational dynamics. Chem Res Toxicol 14:338-347.
3. Ekins S, Ring BJ, Binkley SN, Hall SD, and Wrighton SA (1998) Autoactivation and activation of the cytochrome P450s. Int J Clin Pharmacol Ther 36:642-651.
4. Gill HJ, Tingle MD, and Park BK (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40:531-538.
5. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano P ed) pp 473-535, Plenum Press, New York.
6. Hanioka N, Gonzalez FJ, Lindberg NA, Liu G, Gelhoin HV, and Korzekwa KR (1992) Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2: Influence of the distal helix on the kinetics of testosterone hydroxylation. Biochemistry 31:3364-3370.
7. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci 95:6636-6641.
8. He M, Korzekwa KR, Jones JP, Rettie AE, and Trager WF (1999) Structurul forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372:16-28.
9. Hutzler JM, Hauer MJ, and Tracy TS (2001) Dapsone activation of CYP2C9-mediated metabolism: Evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 29:1-6.
10. Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS, and Smith DA (1996b) Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab Dispos 24:260-266.
11. Jones JP, He M, Trager WF, and Rettie AE (1996a) Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 24:1-6.
12. Korzekwa KR and Jones JP (1993) Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics 3:1-18.
13. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites, Biochemistry 37:4137-4147.
14. Mancy A, Broto P, Dijols S, Dansette PM, and Mansuy D (1995) The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34:10365-10375.
15. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
16. Perret A and Pompon D (1998) Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms. Biochemistry 37:11412-11424.
17. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: A role for P4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
18. Ridderstrom M, Masimirembwa CM, Trump-Kallmeyer S, Ahlefelt M, Otter C, and Andersson TB (2000) Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem Biophys Res Commun 270:983-987.
19. Schwab GE, Raucy JL, and Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol Pharmacol 33:493-499.
20. Segal I (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. John Wiley & Sons, Inc., New York.
21. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
22. Thummel KE, Kunze KL, and Shen DD (2000) Metabolically-based drug-drug interactions: Principles and mechanisms, in Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD, and Eichelbaum M eds) pp 3-19, Lippincott Williams & Wilkins, Philadelphia.
23. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, and Birkett DJ (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175:1112-1118.
24. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AYH (2000) Human cytochrome P450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
25. Winter HR, Wang Y, and Unadkat JD (2000) CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos 28:865-868.
26. Wrighton SA, and Stevens JC (1992) The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.